تاريخ مجلس الدراسات العليا

2021-06-12

اسم الطالب

نور رضوان فخرالدين اشقر

ملخص الرسالة

The use of pulmonary route for drug delivery is currently more applicable in comparison with other routes of drug administration for treatment of pulmonary disorders. Since dry powder inhaler has favorable properties, it was the focus of the present work. The main aim of the present study was to develop a dry powder inhaler of fluticasone propionate for pediatric use using novel technologies that overcome common dry powder inhaler challenges. In our work we employed nanotechnology to optimize fluticasone propionate carried by polymer based on tyrosine amino acid and interfacial polymerization for the preparation of (poly (esteramides)). The polymer was evaluated and the prepared fluticasone propionate polymer nanoparticles were assessed for efficacy and lung deposition. A quantitative method for the analysis of fluticasone propionate by high performance liquid chromatography was established and validated according to International Council for Harmonization Guidelines. Aerodynamic particle size and lung deposition were assessed using the next generation impactor. Finally, the prepared dry powder inhaler was compared to a marketed brand with the same active ingredient carried by lactoheal carrier. The prepared fluticasone propionate polymer nanoparticles showed promising results. It was found that the emitted dose of the produced formulation was 87.29% while it did not exceed 59% in the marketed product. Fluticasone propionate polymer nanoparticles produced higher respirable dose when compared to the marketed dry powder inhaler (48.63 µg vs. 34.15 µg, respectively). Aerodynamic performance for the new formula and the marketed product was evaluated and our product passed in many stages: fine particle fraction for emitted dose, fine particle fraction for nominal dose, respirable dose, and emitted dose. The content uniformity was evaluated and the nanoparticles produced were reproducible, which contained 100 ?g drug per 20 mg of nanoparticle formulation. It was concluded that the amount of prepared fluticasone propionate in our dry powder inhaler was successfully delivered to the lungs, which could offer a favorable local action in the targeted area of the lung.